Literature DB >> 2863941

Clinical applications of somatostatin analogs.

P Marbach, M Neufeld, J Pless.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 2863941     DOI： 10.1007/978-1-4615-7886-4_19

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  6 in total

1.  Intestinal absorption of octreotide using trimethyl chitosan chloride: studies in pigs.

Authors:  M Thanou; J C Verhoef; J H Verheijden; H E Junginger
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.

Authors:  Dong Hee Na; Kang Choon Lee; Patrick P DeLuca
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

3.  Peroral absorption of octreotide in pigs formulated in delivery systems on the basis of superporous hydrogel polymers.

Authors:  Farid A Dorkoosh; J Coos Verhoef; Jos H M Verheijden; Morteza Rafiee-Tehrani; Gerrit Borchard; Hans E Junginger
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

4.  Noncanonical suppression of GH-dependent isoforms of cytochrome P450 by the somatostatin analog octreotide.

Authors:  Rajat Kumar Das; Sarmistha Banerjee; Bernard H Shapiro
Journal:  J Endocrinol       Date:  2013-01-02       Impact factor: 4.286

5.  Enteral absorption of octreotide: absorption enhancement by polyoxyethylene-24-cholesterol ether.

Authors:  J Drewe; G Fricker; J Vonderscher; C Beglinger
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

6.  Growth hormone-independent suppression of growth hormone-dependent female isoforms of cytochrome P450 by the somatostatin analog octreotide.

Authors:  Sarmistha Banerjee; Rajat Kumar Das; Bernard H Shapiro
Journal:  Eur J Pharmacol       Date:  2013-05-21       Impact factor: 4.432
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.